Retevmo (Selpercatinib) Patent Expiration, LOE Window & CMS Spending

Retevmo (Selpercatinib) by Eli Lilly: FDA Orange Book core substance LOE 2039-04-10, 0 AB generics, $100.2M 2024 CMS Part D & Medicaid spend, and $22,598 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorEli Lilly
FDA Application & PathwayN213246 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-04-10
Last Listed Patent or Exclusivity Date2039-04-10
Orange Book Patents (*PED Extensions)12 patents (6 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$100.2M
2024 Medicare Part D Spend$84.9M
2024 Medicaid Spend$15.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($22,598 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.